QPPV.COM KNOWLEDGE ASSESSMENT

Panitumumab: EGFR Biology, RAS Selection, Colorectal Cancer and Product Pharmacovigilance

Test your understanding of the concepts covered by Panitumumab: EGFR Biology, RAS Selection, Colorectal Cancer and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 How should aggregate safety analyses generally handle panitumumab monotherapy, panitumumab plus FOLFOX and panitumumab plus sotorasib?

Pool all regimens automatically because the panitumumab dose is the same Stratify by regimen and molecular population when these factors may modify risk Exclude combination regimens from all aggregate analyses Analyse only the most severe event in each treatment group

Question 2 of 10 Which statement best reflects the importance of jurisdiction in assessing panitumumab exposure?

The EU and US indications are identical and can be merged for case assessment A RAS-mutant exposure is always unauthorised regardless of regimen Indication, country and regimen should be captured together because the authorised KRAS G12C combination differs by jurisdiction Jurisdiction matters only for batch-number reporting

Question 3 of 10 Which overall case-processing approach best reflects the article's practical framework?

Start with the adverse-event term and omit molecular and regimen information unless requested Confirm jurisdiction and regimen, verify exact molecular context, define the clinical syndrome, reconstruct chronology and assess all relevant exposures Assign every event to panitumumab because it is the biologically targeted medicine Assess only whether the event appears in the product label

Question 4 of 10 What is the main practical distinction between panitumumab's receptor blockade and a mechanism that directly inhibits mutant KRAS?

Panitumumab acts extracellularly at EGFR, whereas mutant KRAS is a downstream signalling node Panitumumab directly repairs RAS mutations in tumour DNA Panitumumab activates EGFR while sotorasib blocks the receptor Both medicines act at exactly the same molecular site

Question 5 of 10 A laboratory report initially transcribes a tumour as RAS wild type, but the original pathology report shows an activating NRAS mutation. What type of pharmacovigilance concern does this most directly raise?

A potential molecular-test or documentation process failure affecting treatment selection Proof that panitumumab binds only mutant RAS A product-quality defect in the panitumumab vial An expected infusion reaction caused by the pathology report

Question 6 of 10 Which information is most important when evaluating a suspected panitumumab infusion reaction?

The exact timing from infusion start, symptoms, vital signs and management Only whether the tumour was RAS-wild type The patient's dermatologic symptoms three months before treatment The number of metastatic sites without any infusion chronology

Question 7 of 10 A patient receiving panitumumab develops dyspnoea and bilateral pulmonary infiltrates. Which approach best reflects the article's PV framework?

Assume interstitial lung disease because pulmonary toxicity is listed Exclude panitumumab immediately without evaluating alternative causes Obtain imaging and evaluate infection, embolism, progression, heart failure and other treatment-related causes Classify the event as an infusion reaction unless it began during administration

Question 8 of 10 Which event is most characteristic of on-target EGFR inhibition in normal tissues rather than a non-specific cytotoxic effect?

Acneiform dermatitis with paronychia and skin-barrier disruption Universal bone-marrow aplasia after every dose Permanent loss of all tumour-specific mutations Immediate correction of hypomagnesaemia

Question 9 of 10 What is the appropriate regulatory action described for confirmed interstitial lung disease associated with panitumumab under the current US label?

Continue treatment without modification because the event is uncommon Permanently discontinue panitumumab Increase the infusion rate to reduce pulmonary exposure Restart immediately after the first dose of antibiotics

Question 10 of 10 Which laboratory pattern is most consistent with the mechanism-informed interpretation of panitumumab-associated electrolyte toxicity?

Progressive hypomagnesaemia with possible secondary hypocalcaemia and hypokalaemia Isolated persistent hypernatremia caused by increased intestinal sodium absorption Acute hypermagnesaemia caused by excessive EGFR activation Progressive thrombocytopenia with no electrolyte abnormalities

Panitumumab: EGFR Biology, RAS Selection, Colorectal Cancer and Product Pharmacovigilance

Cookie Settings